skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Infographic: Key Drug Product Launches 2021

Explore this timely and informative infographic for a view into the indications, drugs, and companies expected to make waves with new releases next year. Biomedtracker brings you evidence-based clinical assessments and insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs set to launch in 2021. 
2021 Key drug Launches infographic

Extract: Key Potential Drug Launches 2021

As a supplement to our well-known quarterly outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2021.

These drugs represent new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.

Key Potential Drug Launches 2021


  • ターゲット市場の実像をつかむ, 世界の薬事規制動向&情報を配信

    Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?

    By Tara Hansen

    The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.

    Topics $name FDA

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Scrip: 世界の医療用医薬品&製薬産業に関するニ...

    39th Annual J.P. Morgan Healthcare Conference 2021

    Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.

  • ターゲット市場の実像をつかむ

    Pharma Must Not Let Its COVID-19 Halo Slip

    By Daniel Chancellor

    Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.

    Topics Coronavirus $name BioPharmaceutical